Hepatic Osteodystrophy—Molecular Mechanisms Proposed to Favor Its Development
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Almost all patients with chronic liver diseases (CLD) show altered bone metabolism. Depending on the etiology, this manifests in a severe osteoporosis in up to 75% of the affected patients. Due to high prevalence, the generic term hepatic osteodystrophy (HOD) evolved, describing altered bone metabolism, decreased bone mineral density, and deterioration of bone structure in patients with CLD. Once developed, HOD is difficult to treat and increases the risk of fragility fractures. Existing fractures affect the quality of life and, more importantly, long-term prognosis of these patients, which presents with increased mortality. Thus, special care is required to support the healing process. However, for early diagnosis (reduce fracture risk) and development of adequate treatment strategies (support healing of existing fractures), it is essential to understand the underlying mechanisms that link disturbed liver function with this bone phenotype. In the present review, we summarize proposed molecular mechanisms favoring the development of HOD and compromising the healing of associated fractures, including alterations in vitamin D metabolism and action, disbalances in transforming growth factor beta (TGF-β) and bone morphogenetic protein (BMP) signaling with histone deacetylases (HDACs) as secondary regulators, as well as alterations in the receptor activator of nuclear factor kappa B ligand (RANKL)–osteoprotegerin (OPG) system mediated by sclerostin. Based on these mechanisms, we give an overview on the limitations of early diagnosis of HOD with established serum markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitamin D metabolism, mechanism of action, and clinical applications
Bikle, D. D. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.12.016 · Cited by 1,933
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Self-citationIdentification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698
Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., & Adcock, I. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050466 · Cited by 638
TGF‐β signalling and liver disease
Fabregat, I., Moreno‐Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., ten Dijke, P., & the IT‐LIVER Consortium (2016) · The FEBS Journal · doi:10.1111/febs.13665 · Cited by 600
Self-citationMice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559
Cell adhesion protein receptors as targets for transforming growth factor-$beta; action
IGNOTZ, R. (1987) · Cell · doi:10.1016/0092-8674(87)90146-2 · Cited by 485
Signaling through the Primary Cilium
Wheway, G., Nazlamova, L., & Hancock, J. T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00008 · Cited by 483
Vitamin D testing and treatment: a narrative review of current evidence
Pilz, S., Zittermann, A., Trummer, C., Theiler-Schwetz, V., Lerchbaum, E., Keppel, M. H., Grübler, M. R., März, W., & Pandis, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0432 · Cited by 276
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271
History of the discovery of vitamin D and its active metabolites
DeLuca, H. F. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2013.213 · Cited by 249
Gallego-Rojo, F. J., Gonzalez-Calvin, J. L., Muñoz-Torres, M., Mundi, J. L., Fernandez-Perez, R., & Rodrigo-Moreno, D. (1998) · Hepatology · doi:10.1002/hep.510280315 · Cited by 241
Bone disorders in chronic liver disease
Collier, J. (2007) · Hepatology · doi:10.1002/hep.21852 · Cited by 238
Crucial Role of Vitamin D in the Musculoskeletal System
Wintermeyer, E., Ihle, C., Ehnert, S., Stöckle, U., Ochs, G., De Zwart, P., Flesch, I., Bahrs, C., & Nussler, A. (2016) · Nutrients · doi:10.3390/nu8060319 · Cited by 216
Self-citationPrimary cilium-dependent signaling mechanisms
Pala, R., Alomari, N., & Nauli, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112272 · Cited by 205
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
Menon, K. V. N., Angulo, P., Weston, S., Dickson, E. R., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00144-1 · Cited by 180 · cited 4×
“…9 Bering et al., 2018 [39] 28 104 27.10 17.09–37.11 0 20 40 60 80 100 ∅ 4 3 2 1 0 20 40 60 80 100 ∅ 3 2 1 0 20 40 60 80 100 ∅ 9 8 7 6 5 4 3 2 1 2 Lindor et al., 1995 [16] 31 88 35.00 22.64–47.36 3 Menon et al., 2001 [14] 35 176 20.00 13.39–26.61 4 Mounach et al., 2008 [15] 17 33 51.50 27.”
InfluentialGuañabens, N., Parés, A., Ros, I., Caballería, L., Pons, F., Vidal, S., Monegal, A., Peris, P., & Rodés, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.035 · Cited by 179
HDAC5 Controls MEF2C-Driven Sclerostin Expression in Osteocytes
Wein, M. N., Spatz, J., Nishimori, S., Doench, J., Root, D., Babij, P., Nagano, K., Baron, R., Brooks, D., Bouxsein, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2381 · Cited by 158
Osteoclast synthesis and secretion and activation of latent transforming growth factor β
Oursler, M. J. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090402 · Cited by 153 · cited 1×
“During bone resorption or fracture, osteoclasts activate TGF-β in their resorption lacuna via proteolytic and acidic hydrolysis [162,163].”
BackgroundGuañabens, N., Cerdá, D., Monegal, A., Pons, F., Caballería, L., Peris, P., & Parés, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.016 · Cited by 142
Diagnostic tests: Bone mineral density: Testing for osteoporosis
Sheu, A., & Diamond, T. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.020 · Cited by 138
Bone disease in patients with primary sclerosing cholangitis
Angulo, P., Grandison, G. A., Fong, D. G., Keach, J. C., Lindor, K. D., Bjornsson, E., & Koch, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.014 · Cited by 133
Current understanding of osteoporosis associated with liver disease
Nakchbandi, I. A., & van der Merwe, S. W. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.166 · Cited by 98
Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol
Santori, C., Ceccanti, M., Diacinti, D., Attilia, M. L., Toppo, L., D’Erasmo, E., Romagnoli, E., Mascia, M. L., Cipriani, C., Prastaro, A., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346365 · Cited by 87
Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease
GARCÍA-VALDECASAS-CAMPELO, E., GONZÁLEZ-REIMERS, E., SANTOLARIA-FERNÁNDEZ, F., DE LA VEGA-PRIETO, M. J., MILENA-ABRIL, A., SÁNCHEZ-PÉREZ, M. J., MARTÍNEZ-RIERA, A., & GÓMEZ-RODRÍGUEZ, M. D. L. Á. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agl004 · Cited by 77
Bering, T., Diniz, K. G. D., Coelho, M. P. P., Vieira, D. A., Soares, M. M. S., Kakehasi, A. M., Correia, M. I. T. D., Teixeira, R., Queiroz, D. M. M., Rocha, G. A., et al. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12269 · Cited by 73 · cited 2×
“…2013 [11] 23 33 69.70 41.22–98.18 6 Orsini et al., 2013 [10] 8 60 13.30 4.07–22-53 7 Lai et al., 2015 [37] 25 60 42.00 –58.40 8 Huang et al., 2017 [38] 54 148 36.30 26.59–46.01 9 Bering et al., 2018 [39] 28 104 27.10 17.09–37.11 Summary 231 634 37.87 27.61–48.13 Studies on patients with viral…”
InfluentialOsteoporosis in liver diseases and after liver transplantation
Hay, J. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00143-0 · Cited by 72
Management of osteoporosis in liver disease
Guañabens, N., & Parés, A. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.03.007 · Cited by 56
Osteoporosis in primary biliary cholangitis
Danford, C. J., Trivedi, H. D., Papamichael, K., Tapper, E. B., & Bonder, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3513 · Cited by 56
Hofmann, W. P., Kronenberger, B., Bojunga, J., Stamm, B., Herrmann, E., Bücker, A., Mihm, U., Von Wagner, M., Zeuzem, S., & Sarrazin, C. (2008) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01038.x · Cited by 51
Bone disorders in patients with chronic liver disease awaiting liver transplantation
Loria, I., Albanese, C., Giusto, M., Galtieri, P. A., Giannelli, V., Lucidi, C., Di Menna, S., Pirazzi, C., Corradini, S. G., Mennini, G., et al. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.03.096 · Cited by 48
Does iron affect osteoblast function? StudiesIn vitro and in patients with chronic liver disease
Diamond, T., Pojer, R., Stiel, D., Alfrey, A., & Posen, S. (1991) · Calcified Tissue International · doi:10.1007/bf02556449 · Cited by 44
Serum sclerostin in alcoholics: a pilot study
González-Reimers, E., Martín-González, C., de la Vega-Prieto, M. J., Pelazas-González, R., Fernández-Rodríguez, C., López-Prieto, J., Alvisa-Negrín, J., & Santolaria-Fernández, F. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/ags136 · Cited by 41
Kim, G., Kim, K. J., Rhee, Y., & Lim, S.-K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182202 · Cited by 38
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
Polyzos, S. A., Anastasilakis, A. D., Kountouras, J., Makras, P., Papatheodorou, A., Kokkoris, P., Sakellariou, G. T., & Terpos, E. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0687-x · Cited by 32
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease
Yurci, A., Kalkan, A. O., Ozbakir, O., Karaman, A., Torun, E., Kula, M., Baskol, M., Gursoy, S., Yucesoy, M., & Bayram, F. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834cd6f6 · Cited by 22
Keller, S., Ittrich, H., Schramm, C., Lohse, A. W., Amling, M., Adam, G., & Yamamura, J. (2016) · Japanese Journal of Radiology · doi:10.1007/s11604-016-0573-z · Cited by 4 · cited 3×
“…26.59–46.01 9 Bering et al., 2018 [39] 28 104 27.10 17.09–37.11 0 20 40 60 80 100 ∅ 4 3 2 1 0 20 40 60 80 100 ∅ 3 2 1 0 20 40 60 80 100 ∅ 9 8 7 6 5 4 3 2 1 2 Angulo et al., 2011 [1] 178 237 75.00 63.97–86.03 3 Keller et al., 2016 [13] 15 40 37.50 18.52–56.48 Summary 2 7 358 43.18 3.44–82.92 Int.”
Influential
Cited by
Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression
Lu, K., Shi, T.-S., Shen, S.-Y., Shi, Y., Gao, H.-L., Wu, J., Lu, X., Gao, X., Ju, H.-X., Wang, W., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.006 · Cited by 126
“Our studies add to the knowledge of a crucial liver-bone axis in maintaining themetabolic homeostasis of the body (Ehnert et al., 2019; Nussler et al., 2014; Wang et al., 2015).”
BackgroundSIRT2 regulates extracellular vesicle-mediated liver-bone communication
Lin, L., Guo, Z., He, E., Long, X., Wang, D., Zhang, Y., Guo, W., Wei, Q., He, W., Wu, W., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00803-0 · Cited by 88
Jadzic, J., Milovanovic, P. D., Cvetkovic, D., Zivkovic, V., Nikolic, S., Tomanovic, N., Djuric, M. P., & Djonic, D. (2022) · Journal of Anatomy · doi:10.1111/joa.13621 · Cited by 14
“…activator for nuclear factor kappa B ligand and osteoprotegerin ratio, altered production of pro- inflammatory cytokines and trophic factors (Ehnert et al., 2019; Guañabens & Parés, 2018; Luo et al., 2017), changes in matrix metalloproteinase activity, or bilirubin and bile acids stasis are…”
BackgroundHosseini-Fard, S. R., Etemad-Moghadam, S., Alaeddini, M., Dehpour, A. R., Emamgholipour, S., & Golestani, A. (2024) · Scientific Reports · doi:10.1038/s41598-023-50547-w · Cited by 6
“Researchers are investigating diverse mechanisms that could potentially serve as targets for these treatments 3 .”
Background
Metadata
- Authors
- Ehnert, S., Aspera-Werz, R. H., Ruoß, M., Dooley, S., Hengstler, J. G., Nadalin, S., Relja, B., Badke, A., & Nussler, A. K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-05-24
- Volume
- 20
- Issue
- 10
- Pages
- 2555
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2946475073
- Cited by
- 72
- References
- 41
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.